Offer Request Form

Order list is empty

Shikari® (QS-VEDO)

Enzyme immunoassay for the specific and quantitative determination of free Vedolizumab (Entyvio®) in serum and plasma.

This kit has been especially developed for the specific and quantitative determination of free vedolizumab (Entyvio®) in serum and plasma samples between the Cmin and Cmax range of concentrations.

 

Vedolizumab Drug Bank Accession Number is DB09033

Vedolizumab is an integrin blocker and anti-inflammatory agent used to manage ulcerative colitis and Crohn's disease in adults with inadequate clinical response to immunomodulators.Vedolizumab is a recombinant humanized IgG1 monoclonal antibody directed against the human lymphocyte α4β7 integrin, a key mediator of gastrointestinal inflammation. It is used in the treatment of moderate to severe active ulcerative colitis and Crohn's disease for patients who have had an inadequate response with, lost response to, or were intolerant to inhibitors of tumor necrosis factor-alpha (TNF-alpha) or other conventional therapies.

Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

All SHIKARI® ELISA kits are suitable for biosimilar work.

All SHIKARI® ELISA kits are produced under ISO 13485 quality system and have CE IVD mark.

For technical inquiry, please contact techsupport@matriksbiotek.com

 

Required Volume (µl) 10
Total Time (min) 100
Sample Serum, plasma
Sample Number 96
Detection Limit (ng/mL) 1
Spike Recovery (%) Between 85-115
Shelf Life (year) 1
Assay type Quantitative
Species Reactivity Human
Storage conditions Store at +4°C. Please refer to protocols.
Shipping conditions At room temperature
# File Action
Safety Data Sheet (SDS) Download
Instructions for Use Download
Validation Report Download

Publications with this drug

# File Action
Cusato, Jessica, et al. "Therapeutic Drug Monitoring as a Tool for the Clinical Outcome Prediction in Vedolizumab-Treated Patients: An Italian Pilot Study." Biomedicines 12.4 (2024): 824. Download